What do we know about the mechanisms of aromatase inhibitor resistance?

Journal of Steroid Biochemistry and Molecular Biology

Volumn 102, Issue 1-5 SPEC. ISS., 2006, Pages 232-240

  Chen, Shiuan ^a   Masri, Selma ^a   Wang, Xin ^a   Phung, Sheryl ^a   Yuan, Yate Ching ^a   Wu, Xiwei ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS;

EID: 33751009646     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2006.09.012     Document Type: Article

References (56)

1. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., Jones S.E., Alvarez I., Bertelli G., Ortmann O., Coates A.S., Bajetta E., Dodwell D., Coleman R.E., Fallowfield L.J., Mickiewicz E., Andersen J., Lonning P.E., Cocconi G., Stewart A., Stuart N., Snowdon C.F., Carpentieri M., Massimini G., and Bliss J.M. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350 (2004) 1081-1092
2. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., Castiglione M., Tu D., Shepherd L.E., Pritchard K.I., Livingston R.B., Davidson N.E., Norton L., Perez E.A., Abrams J.S., Cameron D.A., Palmer M.J., and Pater J.L. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl. Cancer Inst. 97 (2005) 1262-1271
3. Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes J.F., Hoctin-Boes G., Houghton J., Locker G.Y., and Tobias J.S. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
4. Ackerman G.E., Smith M.E., Mendelson C.R., MacDonald P.C., and Simpson E.R. Aromatization of androstenedione by human adipose tissue stromal cells in monolayer culture. J. Clin. Endocrinol. Metab. 53 (1981) 412-417
5. Normanno N., Di Maio M., De Maio E., De Luca A., de Matteis A., Giordano A., and Perrone F. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr. Relat. Cancer 12 (2005) 721-747
6. Dowsett M., Martin L.A., Smith I., and Johnston S. Mechanisms of resistance to aromatase inhibitors. J. Steroid Biochem. Mol. Biol. 95 (2005) 167-172
7. Moy B., and Goss P.E. Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches. Clin. Cancer Res. 12 (2006) 4790-4793
8. Ali S., and Coombes R.C. Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer 2 (2002) 101-112
9. Miller W.R., and O'Neill J. The importance of local synthesis of estrogen within the breast. Steroids 50 (1987) 537-548
10. James V.H., McNeill J.M., Lai L.C., Newton C.J., Ghilchik M.W., and Reed M.J. Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies. Steroids 50 (1987) 269-279
11. Vermeulen A., Deslypere J.P., Paridaens R., Leclercq G., Roy F., and Heuson J.C. Aromatase, 17 beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur. J. Cancer Clin. Oncol. 22 (1986) 515-525
12. Esteban J.M., Warsi Z., Haniu M., Hall P., Shively J.E., and Chen S. Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation. Am. J. Pathol. 140 (1992) 337-343
13. Santen R.J., Martel J., Hoagland M., Naftolin F., Roa L., Harada N., Hafer L., Zaino R., and Santner S.J. Stromal spindle cells contain aromatase in human breast tumors. J. Clin. Endocrinol. Metab. 79 (1994) 627-632
14. Lu Q., Nakmura J., Savinov A., Yue W., Weisz J., Dabbs D.J., Wolz G., and Brodie A. Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers. Endocrinology 137 (1996) 3061-3068
15. Sasano H., Anderson T.J., Silverberg S.G., Santen R.J., Conway M., Edwards D.P., Krause A., Bhatnagar A.S., Evans D.B., and Miller W.R. The validation of new aromatase monoclonal antibodies for immunohistochemistry-a correlation with biochemical activities in 46 cases of breast cancer. J. Steroid Biochem. Mol. Biol. 95 (2005) 35-39
16. Harada N. Aberrant expression of aromatase in breast cancer tissues. J. Steroid Biochem. Mol. Biol. 61 (1997) 175-184
17. Bulun S.E., Price T.M., Aitken J., Mahendroo M.S., and Simpson E.R. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J. Clin. Endocrinol. Metab. 77 (1993) 1622-1628
18. Ma C.X., Adjei A.A., Salavaggione O.E., Coronel J., Pelleymounter L., Wang L., Eckloff B.W., Schaid D., Wieben E.D., Adjei A.A., and Weinshilboum R.M. Human aromatase: gene resequencing and functional genomics. Cancer Res. 65 (2005) 11071-11082
19. Dick I.M., Devine A., and Prince R.L. Association of an aromatase TTTA repeat polymorphism with circulating estrogen, bone structure, and biochemistry in older women. Am. J. Physiol. Endocrinol. Metab. 288 (2005) E989-E995
20. Okobia M.N., Bunker C.H., Zmuda J.M., Ezeome E.R., Anyanwu S.N., Uche E.E., Ojukwu J., Kuller L.H., and Ferrell R.E. Simple tandem repeat (TTTA)n polymorphism in CYP19 (aromatase) gene and breast cancer risk in Nigerian women. J. Carcinog. 5 (2006) 12
21. Fuqua S.A., Wiltschke C., Zhang Q.X., Borg A., Castles C.G., Friedrichs W.E., Hopp T., Hilsenbeck S., Mohsin S., O'Connell P., and Allred D.C. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res. 60 (2000) 4026-4029
22. Osborne C.K., Bardou V., Hopp T.A., Chamness G.C., Hilsenbeck S.G., Fuqua S.A., Wong J., Allred D.C., Clark G.M., and Schiff R. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl. Cancer Inst. 95 (2003) 353-361
23. Bardou V.J., Arpino G., Elledge R.M., Osborne C.K., and Clark G.M. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J. Clin. Oncol. 21 (2003) 1973-1979
24. Dowsett M. Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res. Treat. 82 (2003) S7
25. Cui X., Zhang P., Deng W., Oesterreich S., Lu Y., Mills G.B., and Lee A.V. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol. Endocrinol. 17 (2003) 575-588
26. Ellis M.J., Coop A., Singh B., Mauriac L., Llombert-Cussac A., Janicke F., Miller W.R., Evans D.B., Dugan M., Brady C., Quebe-Fehling E., and Borgs M. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J. Clin. Oncol. 19 (2001) 3808-3816
27. Marcom P.K., Isaacs C., Harris L., Wong Z.W., Kommarreddy A., Novielli N., Mann G., Tao Y., and Ellis M.J. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res. Treat. (2006)
28. Goetz M.P., Rae J.M., Suman V.J., Safgren S.L., Ames M.M., Visscher D.W., Reynolds C., Couch F.J., Lingle W.L., Flockhart D.A., Desta Z., Perez E.A., and Ingle J.N. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23 (2005) 9312-9318
29. Kao Y.C., Okubo T., Sun X.Z., and Chen S. Induction of aromatase expression by aminoglutethimide, an aromatase inhibitor that is used to treat breast cancer in postmenopausal women. Anticancer Res. 19 (1999) 2049-2056
30. Santen R.J., Song R.X., Zhang Z., Kumar R., Jeng M.H., Masamura A., Lawrence Jr. J., Berstein L., and Yue W. Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr. Relat. Cancer 12 Suppl. 1 (2005) S61-S73
31. Santen R.J., Song R.X., Zhang Z., Kumar R., Jeng M.H., Masamura S., Lawrence Jr. J., MacMahon L.P., Yue W., and Berstein L. Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. J. Steroid Biochem. Mol. Biol. 95 (2005) 155-165
32. Chan C.M., Martin L.A., Johnston S.R., Ali S., and Dowsett M. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J. Steroid Biochem. Mol. Biol. 81 (2002) 333-341
33. Martin L.A., Farmer I., Johnston S.R., Ali S., Marshall C., and Dowsett M. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J. Biol. Chem. 278 (2003) 30458-30468
34. Nicholson R.I., Staka C., Boyns F., Hutcheson I.R., and Gee J.M. Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocr. Relat. Cancer 11 (2004) 623-641
35. Staka C.M., Nicholson R.I., and Gee J.M. Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model. Endocr. Relat. Cancer 12 Suppl. 1 (2005) S85-S97
36. Sabnis G.J., Jelovac D., Long B., and Brodie A. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res. 65 (2005) 3903-3910
37. Zhou D.J., Pompon D., and Chen S.A. Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res. 50 (1990) 6949-6954
38. Berstein L.M., Zheng H., Yue W., Wang J.P., Lykkesfeldt A.E., Naftolin F., Harada H., Shanabrough M., and Santen R.J. New approaches to the understanding of tamoxifen action and resistance. Endocr. Relat. Cancer 10 (2003) 267-277
39. Gutierrez M.C., Detre S., Johnston S., Mohsin S.K., Shou J., Allred D.C., Schiff R., Osborne C.K., and Dowsett M. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J. Clin. Oncol. 23 (2005) 2469-2476
40. Hutcheson I.R., Knowlden J.M., Madden T.A., Barrow D., Gee J.M., Wakeling A.E., and Nicholson R.I. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res. Treat. 81 (2003) 81-93
41. Nabha S.M., Glaros S., Hong M., Lykkesfeldt A.E., Schiff R., Osborne K., and Reddy K.B. Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells. Oncogene 24 (2005) 3166-3176
42. Schafer J.M., Bentrem D.J., Takei H., Gajdos C., Badve S., and Jordan V.C. A mechanism of drug resistance to tamoxifen in breast cancer. J. Steroid Biochem. Mol. Biol. 83 (2002) 75-83
43. Shou J., Massarweh S., Osborne C.K., Wakeling A.E., Ali S., Weiss H., and Schiff R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl. Cancer Inst. 96 (2004) 926-935
44. Jelovac D., Sabnis G., Long B.J., Macedo L., Goloubeva O.G., and Brodie A.M. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res. 65 (2005) 5380-5389
45. Brodie A., Jelovac D., Sabnis G., Long B., Macedo L., and Goloubeva O. Model systems: mechanisms involved in the loss of sensitivity to letrozole. J. Steroid Biochem. Mol. Biol. 95 (2005) 41-48
46. Bertelli G., Garrone O., Merlano M., Occelli M., Bertolotti L., Castiglione F., Pepi F., Fusco O., Del Mastro L., and Leonard R.C. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 69 (2005) 471-477
47. Macedo L.F., Guo Z., Tilghman S.L., Sabnis G.J., Qiu Y., and Brodie A. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res. 66 (2006) 7775-7782
48. Sun X.Z., Zhou D., and Chen S. Autocrine and paracrine actions of breast tumor aromatase. A three-dimensional cell culture study involving aromatase transfected MCF-7 and T-47D cells. J. Steroid Biochem. Mol. Biol. 63 (1997) 29-36
49. Frasor J., Danes J.M., Komm B., Chang K.C., Lyttle C.R., and Katzenellenbogen B.S. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144 (2003) 4562-4574
50. Frasor J., Stossi F., Danes J.M., Komm B., Lyttle C.R., and Katzenellenbogen B.S. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res. 64 (2004) 1522-1533
51. Itoh T., Karlsberg K., Kijima I., Yuan Y.C., Smith D., Ye J., and Chen S. Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach. Mol. Cancer Res. 3 (2005) 203-218
52. Thompson Jr. E.A., and Siiteri P.K. Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. J. Biol. Chem. 249 (1974) 5364-5372
53. Omoto Y., and Hayashi S. A study of estrogen signaling using DNA microarray in human breast cancer. Breast Cancer 9 (2002) 308-311
54. Treeck O., Zhou R., Diedrich K., and Ortmann O. Tamoxifen long-term treatment in vitro alters the apoptotic response of MCF-7 breast cancer cells. Anticancer Drugs 15 (2004) 787-793
55. Becker M., Sommer A., Kratzschmar J.R., Seidel H., Pohlenz H.D., and Fichtner I. Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol. Cancer Ther. 4 (2005) 151-168
56. Wu Z., Irizarry R.A., Gentleman R., Murillo F., and Spencer F.A. Model Based Background Adjustment for Oligonucleotide Expression Arrays (2004), John Hopkins University, Baltimore